Central Melanocortin Mechanism
Bremelanotide is a non-selective MC receptor agonist; presynaptic MC4R activation in the medial preoptic area increases dopamine release and drives sexual arousal centrally.
[1]A synthetic cyclic heptapeptide and analog of alpha-MSH, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. PT-141 acts centrally on melanocortin receptors in the hypothalamus, driving dopamine release in arousal circuits, a mechanism entirely distinct from peripheral PDE5 inhibitors.
At a glance
- Type
- Synthetic cyclic heptapeptide, analog of alpha-MSH
- Mechanism
- Central melanocortin (MC4R) agonist acting in the hypothalamus
- Regulatory
- FDA-approved as Vyleesi for HSDD in premenopausal women
- Route
- Subcutaneous, as needed about 2 hours before sexual activity
- Onset and duration
- Onset 30 to 90 minutes; duration several hours
- Frequency limit
- No more than 8 doses per month, at least 24 hours apart
What the research supports
PT-141 has FDA approval, decades of preclinical work in the central melanocortin pathway, and modern meta-analyses defining its real-world effect size.
HSDD Meta-Analysis
Bremelanotide improves total Female Sexual Function Index scores and the desire and arousal subscales in women with HSDD with small to modest effect sizes.
[4]Independent Effect-Size Reanalysis
Phase III RECONNECT trial reanalysis confirms a real but modest effect; several efficacy outcomes have limited validity evidence in the target population.
[3]Central Melanocortin Class Review
The central melanocortin system is a productive target for both metabolic and sexual conditions; setmelanotide for syndromic obesity supports the broader class.
[2]Summary of key findings
FDA-Approved Indication
Vyleesi is approved for premenopausal HSDD; PT-141 has regulatory standing most peptides lack.
Modest but Real Efficacy
Effect size is small to modest in HSDD trials and meta-analyses; expectations should be set accordingly.
Nausea is Dose-Limiting
Starting at 500 mcg and pre-dosing with ginger or low-dose ondansetron mitigates the dominant adverse effect.
Central, Not Peripheral
Mechanism is brain-based dopamine release in arousal circuits, distinct from and complementary to PDE5 inhibitors.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- HSDD On-Demand Protocol
- 500 mcg to 1 mg subcutaneous as needed approximately 2 hours before sexual activity. Onset 30 to 90 minutes; duration several hours.
- Maximum Frequency
- No more than 8 doses per month with at least 24 hours between doses; do not exceed 1 mg per dose without physician supervision.
- Titration
- Start at 500 mcg. Nausea is dose-dependent; titrate upward only if needed and tolerated.
- Combined Therapy (Men)
- Can be combined with PDE5 inhibitors in selected cases due to non-overlapping mechanisms; coordinate with the prescribing urologist.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| PT-141 5 mg / 1 mL | 500 mcg | 10 units | As needed, 2 hours pre-activity | 0.05 mg per unit. PM empty stomach. |
| PT-141 10 mg / 2 mL | 500 mcg to 1 mg | 10 to 20 units | As needed, 2 hours pre-activity | 0.05 mg per unit. Not to exceed 20 units. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
PT-141 is the only FDA-approved peptide for sexual desire and one of the few peptides with a regulatory standing that supports patient confidence and documentation. Frame the effect as desire enhancement, not mechanical erection, since the peptide acts in the brain rather than the vasculature. Effect sizes in HSDD trials are modest; manage expectations. Nausea is dose-limiting and dose-dependent. Skin darkening with frequent repeated use is the cosmetic concern patients ask about most. The peptide combines well with PDE5 inhibitors in men since mechanisms are non-overlapping.
Desire Enhancement
Centrally driven libido and arousal in men and women
Distinct Mechanism
Central MC4R pathway, complementary to peripheral PDE5 inhibitors
On-Demand Protocol
500 mcg to 1 mg SC, 2 hours before activity, up to 8x monthly
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Pfaus et al., 2021 The neurobiology of bremelanotide for HSDD in premenopausal women
- 2Sweeney et al., 2023 Targeting the central melanocortin system for metabolic disorders
- 3Spielmans and Ellefson, 2023 Bremelanotide for HSDD: small effects, questionable outcomes
- 4Toledo et al., 2025 Female sexual dysfunction treatment meta-analysis
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.